[A preliminary experience of chemotherapy using cisplatin (CDDP) in oral and maxillofacial carcinoma].
During 1984-1986, fifty-one patients, including 42 squamous cell carcinomas, 8 carcinomas of salivary gland origin and 1 malignant histiocytoma, were treated in our hospital using the PVP (CDDP, VCR and PINGYANGMYCIN) regimen or single CDDP. The response rate was 71.4% (30/42) for squamous cell carcinoma (CR 4 cases, PR 26 cases, NR 12 cases) with PVP, and 3/8 (all PR cases) for carcinoma of salivary gland origin (all adenoid cystic carcinomas) with CDDP. The authors indicate that besides the MTX and PINGYANGMYCIN, CDDP is another effective and useful drug for squamous cell carcinoma. When single dose (80-120 mg) is given by infusion with fluid and diuretics, it is very safe and (no need) worry about impairment of kidney function.
Qiu
W L
WL
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D005153:Facial Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007573:Jaw Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D001761:Bleomycin; D014750:Vincristine; C021771:zhengguangmycin; D002945:Cisplatin